8.7 C
Munich
Thursday, May 7, 2026

Receipt of novel hormonal therapy for advanced prostate cancer varies with race

Must read

For Medicare beneficiaries with advanced prostate cancer (PCa), receipt of novel hormonal therapy (NHT) agents varies with race, according to a study published online Dec. 1 in JAMA Network Open…
Read More

- Advertisement -spot_img

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisement -spot_img

Latest article